J Thorac Cardiovasc Surg. 1981 Nov;82(5):649-57.
The Lung Cancer Study Group (LCSG) has tested the efficacy of intrapleural bacillus Calmette-Guérin (BCG) as surgical adjuvant treatment in a double-blind, randomized comparison against intrapleural saline. This clinical trial included specific anatomic and pathological staging requirements and careful follow-up monitoring. At this time, with a median follow-up of 516 days in 216 treated and 209 control patients, no evidence has yet been found that postoperative instillation of intrapleural BCG improves survival or extends the disease-free interval in patients with completely resected Stage I squamous cell carcinoma, adenocarcinoma, or large cell carcinoma of the lung. There have been 93 recurrences and 77 deaths, which are remarkably evenly distributed in both arms of the study. An unexpectedly superior survival rate for the Stage I group has been observed, and the prognostic importance of cell type, TN status, and elevations in initial white cell count and alkaline phosphatase measurement has been confirmed.
肺癌研究组（LCSG）在一项双盲、随机对照试验中，对比了胸膜内注射卡介苗（BCG）与胸膜内注射生理盐水作为手术辅助治疗的疗效。该临床试验纳入了特定的解剖学和病理学分期要求，并进行了仔细的随访监测。目前，在216例接受治疗的患者和209例对照患者中，中位随访时间为516天，尚未发现术后胸膜内注射BCG能提高完全切除的Ⅰ期肺鳞状细胞癌、腺癌或大细胞癌患者的生存率或延长无病生存期。已有93例复发和77例死亡，在研究的两组中分布非常均匀。观察到Ⅰ期组的生存率出人意料地更高，并且证实了细胞类型、TN状态以及初始白细胞计数和碱性磷酸酶测量值升高的预后重要性。
